Advancement in preoperative desensitization therapy for ABO incompatible kidney transplantation recipients

Transpl Immunol. 2023 Oct:80:101899. doi: 10.1016/j.trim.2023.101899. Epub 2023 Jul 9.

Abstract

ABO incompatibility has long been considered an absolute contraindication for kidney transplantation. However, with the increasing number of patients with ESRD in recent years, ABO-incompatible kidney transplantation (ABOi-KT) has expanded the types of donors by crossing the blood group barrier through preoperative desensitization therapy. At present, the desensitization protocols consist of removal of preexisting ABO blood group antibody titers and prevention of ABO blood group antibody return. Studies have suggested similar patient and graft survival among ABOi-KT and ABOc-KT recipients. In this review, we will summarize the effective desensitization regimens of ABOi-KT, aiming to explore effective ways to improve the success rate and the long-term survival rate of ABOi-KT recipients.

Keywords: ABO incompatible kidney transplantation; Antibody; Basiliximab; Desensitization; Rituximab.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ABO Blood-Group System
  • Antibodies
  • Blood Group Incompatibility
  • Graft Rejection / prevention & control
  • Graft Survival
  • Humans
  • Immunosuppression Therapy / methods
  • Kidney Transplantation*
  • Living Donors

Substances

  • ABO Blood-Group System
  • Antibodies